Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients.
Barrichello APC, Elkrief A, Ricciuti B, Ganta T, Marron TU, Wang X, Lotter W, Lindsay J, Santo V, Cortellini A, Sharma B, Felt K, Pfaff K, Lamberti G, Pecci F, Federico AD, Makarem M, Gandhi MM, Nguyen T, Haradon D, Vaz VR, Johnson BE, Debnath N, Wang Y, Kuang AG, Saeed A, Radford M, Lovly CM, Nebhan CA, Pinato DJ, Rodig SJ, Schoenfeld AJ, Awad MM, Alessi JV, Naqash AR.
Barrichello APC, et al. Among authors: gandhi mm.
Clin Lung Cancer. 2025 Feb 4:S1525-7304(25)00025-7. doi: 10.1016/j.cllc.2025.01.014. Online ahead of print.
Clin Lung Cancer. 2025.
PMID: 40021433